## **PATENTSCOPE:** what's new?



Speaker: Christophe Mazenc,

Director, Global Databases Division, Global Infrastructure Sector



## **Patent Information news**

- Full text
- PATENTSCOPE coverage
- Chemical compounds search



# **About full text**

- In the last 16 months, WIPO and EPO joined forces in order to achieve faster results in the Quality at source project
- Goal: assist patent offices in producing high quality full text for their front file publication in their country language to obtain searchable and machine translatable patent information (Espacenet, PATENTSCOPE)
- How: WIPO puts at disposition to member states its internal OCR / PDF handling technology and WIPO and EPO together train offices to set it up and start production

## **About full text**

- 17 European offices trained so far (CH, BA, BE\*, BG, CY, DK, EE, ES, FI, GR, LT, LV, MT, NO, RO, RS, SE, SK)
- In operations: Front file full text data received from Denmark, Italy, Romania and Greece
- Next: train Latin American Countries (collaboration EPO, SPTO, WIPO)



# **About full text**

RIVENDICAZIONI

- 1) Il device indossato dallo studente, consente suo stesso punto di vista e pertanto di pi valutazioni accurate e capire meglio l'azione dei 2) Il sistema è caratterizzato dal fatto che fa permettono una interattività completa, in form aumentata, docente/studente su due canali. video ed audio, è possibile anche lo scambio immagini modificate su fermo-immagine realizzi studente:
- 3) la possibilità per gli studenti, di rivedere le le commenti del docente
- potere gestire l'intero sistema sia in sito cl cloud.

## FIRMADEL RICI

### CLAIMS

- The wearable device by the student, have his own point of view and therefore assessments and understand the action of the
- 2. The system is characterized by the use full digital interactivity with augmented reality

### $_{ m LF}$

<claim-text>1) Il device indossato dallo studente, consente al docente, di
avere il suo stesso punto di vista e pertanto di potere effettuare delle
valutazioni accurate e capire meglio l&apos; azione dello studente;

</claim-text>LF

<claim-text>2) Il sistema è caratterizzato dal fatto che fa uso di
dispositivi che permettono una interattività completa, in forma digitale,
con realtà aumentata, docente/studente su due canali. Oltre allo scambio
di video ed audio, è possibile anche lo scambio di bozzetti grafici ed
immagini modificate su fermo-immagine realizzato dalle riprese dello
studente;</claim-text>III

<claim-text>3) la possibilità per gli studenti, di rivedere le lezioni,
con gli specifici commenti del docente</claim-text>

<claim-text>4) · potere · gestire · 1&apos; intero · sistema · sia · in · sito · che
tramite · piattaforme · cloud. </claim-text>IF

## 7

</claim>

</claims>

‡<claims∙id="claims"·lang="en">**IF** 

delaim.id="clm-0001".num.="0001"><claim-text>CLAIMS</claim-text>III

### LF


<claim-text>1. The wearable device by the student, allows the teacher to
have his own point of view and therefore he can make, better assessments
and understand the action of the student;</claim-text>

-<claim-text>2. The System is characterized by the use of devices that
allow a full digital interactivity with augmented reality, teacher /
student on

<!-- EPO <DP n="10"/>-->two separate channels. In addition to the exchange

# **News about PATENTSCOPE coverage**

great progress in recent years



Cf. https://patentscope.wipo.int/search/en/help/data\_coverage.jsf

# News about PATENTSCOPE coverage

- Now, 52 patent collections and a total of 71 million patent applications
- Last added collection: India (Bibliographic data only) 480'000 records published from 2005 to 2018
- Collections to come (with front file full text):

Italy

Romania

Greece

# News about PATENTSCOPE functionality


An improved more modern User Interface





# News about PATENTSCOPE functionality

A chemical search functionality expanded to cover all IP5 collections and languages with 5.7 million documents parsed for chemical compounds and counting:



Number of patent applications in PATENTSCOPE with parsed chemical compounds



# News about PATENTSCOPE functionality


This allows get a quick draft patent landscape for drugs in the IP5 offices and to answer tough questions like:

What is the oldest Japanese patent referencing "Valsartan"?

Wikipedia says: "Valsartan (trade name Diovan) is mainly used for treatment of <a href="https://high.nigh.nigh.com/high.blood/pressure">high blood/pressure</a>, <a href="congestive heart failure">congestive heart failure</a>, and to increase the chances of living longer after a <a href="heart attack">heart attack</a>. It is an <a href="angiotensin II receptor antagonist">angiotensin receptor antagonist</a> (commonly called an ARB, or angiotensin receptor blocker), that is selective for the <a href="type I (AT1)">type I (AT1)</a> angiotensin receptor".










Search International and National Patent Collections



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION








Search International and National Patent Collections




**WIPO** WORLD INTELLECTUAL PROPERTY ORGANIZATION










【請求項8】 (S) -N-(1-カルボキシ-2-メチル-プロプ-1-イル) -N-ペンタノイル-N-(2'-(1H-テトラゾール-5-イル) ビフェニル-4-イルメ



[-テトラゾール-5-イル) ビフェニル-4-イルメチル) -アミン、 「ル-N-(2'-(1H-テトラゾール-5-イル) -ビフェニル-4-イルメチル) -ア

[2'- (1H-テトラゾール-5-イル) -ビフェニル-4-イルメチル) -アミン、 - (2'- (1H-テトラゾール-5-イル) -ビフェニル-4-イルメチル) -アミン、 N- (2'- (1H-テトラゾール-5-イル) -ビフェニル-4-イルメチル) -アミ

【イル-N-〔2'-(1H-テトラゾール-5-イル)-ビフェニル-4-イルメチル〕-

(ル-N-(2'-1H-テトラゾール-5-イル)-ビフェニル-4-イルメチル)-アミ

. H-テトラゾール-5-イル)-ビフェニル-4-イルメチル)-アミン、 ニル-N-(2'-(1H-テトラゾール-5-イル)-ビフェニル-4-イルメチル)-

カルボニル-N-(2'-(1H-テトラゾール-5-イル)-ビフェニル-4-イルメチ

「一テトラゾール-5-イル)-ビフェニル-4-イルメチル)-アミン、

プ(2'- (1 H-テトラゾール-5-イル) -ビフェニル-4-イルメチル) -アミン、

N-(1-カルボキシシクロヘキシル)-N-ペンタノイル-N-(2'-(1H-テトラゾール-5-イル)-ビフェニル-4-イルメチル)-アミン、

(S) -N-(1-Pミノカルボニル-2-メチル-プロプ-1-イル) -N-ペンタノイル-N-(2'-(1H-テトラゾール-5-イル) -ビフェニル-4-イルメチル) - アミン、または

(S) -N-(1-力ルボキシ-2-メチループロプ-1-イル) -N-(5-オキソペント-1-エン-5-イル) -N-(2'-(1H-テトラゾール-5-イル) -ビフェニル -4-イルメチル) -アミンである請求項1の化合物または各々の場合のそれらの塩。

【請求項10】 有効成分として遊離形態または医薬として許容されうる塩の形態にある請求項1~9のいずれか1項に記載の化合物を含有する、アンギオテンシン(II) の増加に関連する疾患又は状態の治療のための医薬製剤。

【請求項11】 高血圧又は心機能不全の治療のための、請求項10に記載の医薬組成物。

【請求項12】 ((S)−N−(1−カルボキシ−2−メチル−プロプ−1−イル)−N−ペンタノイル−N−〔2′−(1H−テトラゾル−5−イル)−ビフェニル−4−イルメ チル)−アミン 又はその医薬として許容される塩を含んで成る、請求項10又は11に記載の医薬組成物。

【請求項13】 次の式(I):

(化4)

$$R_1-X_1-N-X_3$$

$$\downarrow$$

$$X_2-R_2$$
 $A$ 

$$R_3$$
 (I),